MedDataX Logo

BTT-1023 in Rheumatoid Arthritis

NCT ID: NCT00851240

Last Updated: 2012-02-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis

NCT00771329

Rheumatoid Arthritis
COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis

NCT01853033

Rheumatoid Arthritis
COMPLETED PHASE1

Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis

NCT00292422

Rheumatoid Arthritis
COMPLETED PHASE2

Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study

NCT02433340

Rheumatoid Arthritis
COMPLETED PHASE2

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293

Rheumatoid Arthritis
COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BTT1023

Group Type EXPERIMENTAL

BTT-1023

Intervention Type DRUG

intravenous

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Intravenous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BTT-1023

intravenous

Intervention Type DRUG

Placebo

Intravenous

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult-onset rheumatoid arthritis

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotie Therapies Corp.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antero Kallio, MD

Role: STUDY_DIRECTOR

Biotie Therapies Corp.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sofia, Bulgaria

Sofia, , Bulgaria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bulgaria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BTT12-CD015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study in Rheumatoid Arthritis
NCT01253265 COMPLETED PHASE1
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
NCT01751776 COMPLETED PHASE1
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
NCT01741493 COMPLETED PHASE1
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
NCT01481493 COMPLETED PHASE2
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
NCT01636843 TERMINATED PHASE2
A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
NCT00308282 COMPLETED PHASE2
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
NCT03001219 TERMINATED PHASE2
Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate
NCT00928317 TERMINATED PHASE2
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis
NCT01223911 COMPLETED PHASE2
Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis
NCT01370902 COMPLETED PHASE1
Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis
NCT00810836 COMPLETED PHASE2
Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects
NCT01287858 COMPLETED PHASE1
Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis
NCT01282255 COMPLETED PHASE2
First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis
NCT00927927 COMPLETED PHASE1
Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis
NCT00760864 COMPLETED PHASE2
A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis
NCT01317797 COMPLETED PHASE1
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT05638854 RECRUITING PHASE1
Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis
NCT02251210 COMPLETED PHASE2
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
NCT07237659 RECRUITING PHASE1
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis
NCT00718588 TERMINATED PHASE1
Remission and Joint Damage Progression in Early Rheumatoid Arthritis
NCT00122382 COMPLETED PHASE3
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
NCT00443651 COMPLETED PHASE3
Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis
NCT01999192 TERMINATED PHASE2
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
NCT01682512 TERMINATED PHASE3
A Study of TJ003234 in Rheumatoid Arthritis Patients
NCT04457856 UNKNOWN PHASE1